The treatment of COVID-19 in immunosuppressed patients is still a mystery. Increased mortality and morbidity are an expected result in patients with hematological malignancies and solid organ transplantation [3]. It is obvious that in patients with hematological malignancies, both innate and humoral immunity weaken due to the primary disease and the agents used in disease treatment. Currently, there is no standard treatment for COVID-19. The agents used are mostly antiviral drugs such as favipravir, remdesivir, lopinavir-ritonavir, oseltamivir. Immune convalescent plasma therapy is a promising treatment in this respect. The use of convalescent plasma is recommended in patients with solid organ transplantation, hematological malignancy and low immunity [5]. Adding to this, it is advised that antiviral therapy and convalescent plasma treatments are used in combination [6]. When the current literature is reviewed, it has been observed that convalescent therapy is mostly used in patients with advanced stage, such as acute respiratory distress syndrome [7,8]. Data on the use of convalescent plasma in the treatment of hematological cancer patients with COVID-19 infection is very limited. However, it has been reported as an effective and safe treatment [5]. Similar to our case, convalescent plasma can be used as a safer treatment in patients with comorbidities such as kidney failure and in which not all drugs can be used.

In a study of 17 patients receiving anti-B-cell treatments, it was reported that the effectiveness of convalescent plasma treatment emerged in a short period of 1 week [9]. In the result of Senefeld’s work, within 48 hours of convalescent plasma transfusion the majority of 54 patients who have hematological malignancies demonstrated improved clinical status and viral clearance [10]. In addition, it was reported that the convalescent plasma administered in a non-Hodgkin Lymphoma patient who was seronegative and whose complaints continued even 88 days of viral meeting. After the onset of plasma his complaints relieved immediately [11]. In another case, convalescent plasma was transfused a patient who was on the day 20 of hospitalization. Following this treatment, the patient became independent of ECMO within one day and was successfully weaned from mechanical ventilation within two days [12]. In addition, a report of 16 patients in USA says steady improvement in oxygenation levels was observed following each convalescent plasma infusion. All of the 5 intubated patients were extubated between 1- and 19-days post convalescent plasma infusion. The remaining 11 showed a dramatic decline in oxygen needs and did not require ventilatory support [13].

We observed that asymptomatic COVID-19 infection was effectively treated with convalescent plasma in a young patient with Hodgkin lymphoma, acute renal failure and who received anti CD-20 therapy. As stated in some studies in the literature, we saw that our patient turned negative for the COVID-19 PCR test within 1 week [14]. When it was given inside of the 72 hours of admission, convelesant plasma recipients <65 years had 4-fold lower mortality and 4-fold lower deterioration in oxygenation on severe Covid-19 patients [15]. In another 3 studies, it was stated that when convalescent plasma is used at an average of 44 and 72 hours, it reduces mortality on the elderlypatients. It should be used in the early periodespecially before cytokine storm begins [16-18]. In the meta-analysis of 17 studies, 5 of which were randomized, it was reported that the mortality rates of patients who received convalescent plasma were significantly lower than those who did not [19]. FDA (United States Food and Drug Administration) announces best outcomes occur in thosewho receive a high-titer unit of convalescent plasma within 3 days of COVID-19 diagnosis or admission to the hospital [20]. We think that the clinical improvement of the patient situation may be due to other drugs used in combination with convalescent plasma. Convalescent plasma can be used as an additive therapy agent in such patients where there is no standard treatment and the mortality rate is high due to the underlying disease. Finally, this treatment may be more effective in asymptomatic andimmunosuppressed patients when it is given as soon as they are diagnosed.